Thalidomide analogs

Details Thalidomide analogs Thalidomide analogs

2011-07-05

2011-07-05

Royds Draper, Leslie A. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S201000, C546S221000, C514S183000

Reexamination Certificate

active

07973057

ABSTRACT:
Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-α) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.

REFERENCES:
patent: 2830991 (1958-04-01), Keller et al.
patent: 3314953 (1967-04-01), Aristotle et al.
patent: 3320270 (1967-05-01), Grogan et al.
patent: 3560495 (1971-02-01), Frankus et al.
patent: 3794641 (1974-02-01), Görög et al.
patent: 4092147 (1978-05-01), Ashkar et al.
patent: 4291048 (1981-09-01), Gold et al.
patent: 5434170 (1995-07-01), Andrulis, Jr.
patent: 5593900 (1997-01-01), D'Amato
patent: 5593990 (1997-01-01), D'Amato
patent: 5605684 (1997-02-01), Piacquadio
patent: 5629327 (1997-05-01), D'Amato
patent: 5712291 (1998-01-01), D'Amato
patent: 5783605 (1998-07-01), Kuo et al.
patent: 5789434 (1998-08-01), Kluender et al.
patent: 5840724 (1998-11-01), Fenton et al.
patent: 6071948 (2000-06-01), D'Amato
patent: 6080742 (2000-06-01), Germann et al.
patent: 6096768 (2000-08-01), Ashton et al.
patent: 6110941 (2000-08-01), Zimmer et al.
patent: 6124322 (2000-09-01), Bjoerkman et al.
patent: 6235756 (2001-05-01), D'Amato
patent: 6306879 (2001-10-01), Germann et al.
patent: 6417197 (2002-07-01), Schneider et al.
patent: 6420414 (2002-07-01), D'Amato
patent: 6458810 (2002-10-01), Muller et al.
patent: 6469045 (2002-10-01), D'Amato
patent: 6500845 (2002-12-01), Boehlke et al.
patent: 6518298 (2003-02-01), Green et al.
patent: 6555554 (2003-04-01), Muller et al.
patent: 6762195 (2004-07-01), Muller et al.
patent: 2001/0041716 (2001-11-01), Laing et al.
patent: 2002/0161023 (2002-10-01), D'Amato
patent: 2003/0013739 (2003-01-01), Masferrer
patent: 2003/0045552 (2003-03-01), Robarge et al.
patent: 2003/0181428 (2003-09-01), Green et al.
patent: 2005/0004087 (2005-01-01), D'Amato et al.
patent: 2104776 (1992-08-01), None
patent: 2251060 (1997-03-01), None
patent: 2228385 (1998-01-01), None
patent: 2248838 (1998-10-01), None
patent: 2302886 (2000-03-01), None
patent: 1 336 602 (2003-08-01), None
patent: 962857 (1964-07-01), None
patent: 1049283 (1966-11-01), None
patent: 1075420 (1967-07-01), None
patent: WO 92/18496 (1992-10-01), None
patent: WO 94/20085 (1994-09-01), None
patent: WO 95/17154 (1995-06-01), None
patent: WO 96/20705 (1996-07-01), None
patent: WO 96/20926 (1996-07-01), None
patent: WO 97/12625 (1997-04-01), None
patent: WO 97/23457 (1997-07-01), None
patent: WO 97/37988 (1997-10-01), None
patent: WO 97/45117 (1997-12-01), None
patent: WO 98/03502 (1998-01-01), None
patent: WO 98/19649 (1998-05-01), None
patent: WO 98/25895 (1998-06-01), None
patent: WO 99/13873 (1999-03-01), None
patent: WO 99/58096 (1999-11-01), None
patent: WO 99/59960 (1999-11-01), None
patent: WO 02/064083 (2002-08-01), None
patent: WO 02/068414 (2002-09-01), None
patent: WO 03/014315 (2003-02-01), None
patent: WO 03/097052 (2003-11-01), None
patent: WO 2004/085422 (2004-10-01), None
patent: WO 2005/016326 (2005-02-01), None
Voss, Juergen, 2,4-Bis(4-methoxyphenyl)-1,3,2,4-dithiaphosphetane, 2001, Encyclopedia of Reagents for Organic Synthesis (e-EROS). Abstract only.
Patani et al., Bioisosterism: A Rational Approach in Drug Design, 1996, Chem. Rev., vol. 96, pp. 3147-3176.
Bray et al., “Improved Procedures for the Preparation of (+)—(1R, 2S, 4R)-4-Amino-2-Hydroxy-1-Hydroxymethyl Cyclopentane,”Tetrahedron Letters36(25):4483-4486, 1995.
Cava et al., “Thionation Reactions of Lawesson's Reagents,”Tethrahedron41(22):5061-5087, 1985.
Corral et al., “Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues that are Potent Inhibitors of TNF-α,”The Journal of Immunology163:380-386, 1999.
Deckers et al., “Effect of Angiogenic and Antiangiogenic Compounds on the Outgrowth of Capillary Structures from Fetal Mouse Bone Explants,”Laboratory Investigation81(1):5-15, 2001.
Dredge et al., “Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination is Mediated by Increased Th1-Type Immunity,”The Journal of Immunology168:4914-4919, 2002.
Greig et al., “Thalidomide-based TNF-α inhibitors for neurodegenerative diseases,”Acta Neurobiol Exp64:1-9, 2004.
Hashimoto et al., “Novel Biological Response Modifiers Derived from Thalidomide,”Current Medicinal Chemistry5:163-178, 1998.
Hashimoto et al., “Structural Development of Biological Response Modifiers Based on Thalidomide,”Bioorganic&Medicinal Chemistry10:461-479, 2002.
Lentzsch et al., “S-3-Amino-phthalimido-glutarimide Inhibits Angiogenesis and Growth of B-Cell Neoplasias in Mice,”Cancer Research62:2300-2305, 2002.
Luzzio et al., “Thalidomide metabolites and analogs. Part 2: Cyclic derivatives of 2-N-phthalimido-2S,3S (3-hydroxy) ornithine,”Tetrahedron Letters41:7151-7155, 2000.
Luzzio et al., “Thalidomide Metabolites and Analogues. 3. Synthesis and Antiangiogenic Activity of the Teratogenic and TNF-α-Modulatory Thalidomide Analogue 2-(2,6-Dioxopiperidine-3-yl)phthalimidine,”Journal of Medicinal Chemistry46(18):3793-3799, 2003.
Marriott et al., “CC-3052: A Water-Soluble Analog of Thalidomide and Potent Inhibitor of Activation-Induced TNF-α Production,”The Journal of Immunology161:4239-4243, 1998.
Meierhofer et al., “New Insights into the pharmacological and toxicological effects of thalidomide,”Current Opinion in Drug Discovery&Development6(1):92-99, 2003.
Miyachi et al., “Inducer-Specific Regulators of Tumor Necrosis Factor Alpha Production,”Chem. Pharm. Bull44(10):1980-1982, 1996.
Miyachi et al., “Novel Biological Response Modifiers: Phthalimides with Tumor Necrosis Factor-α Production-Regulating Activity,”J. Med. Chem.40(18):2858-2865, 1997.
Orzeszko et al., “Tumor necrosis factor-alpha production-regulating activity of phthalimide derivatives in genetically modified murine melanoma cells B78H1,”Il Farmaco58:371-376, 2003.
Shah et al., “Synthesis and Enantiomeric Separation of 2-Phthalimidino-glutaric Acid Analogues: Potent Inhibitors of Tumor Metastasis,”J. Med. Chem.42(16):3014-3017, 1999.
Shimazawa et al., “Nonpeptide Small-Molecular Inhibitors of Dipeptidyl Peptidase IV: N-Phenylphthalimide Analogs,”Bioorganic&Medicinal Chemistry Letters9:559-562, 1999.
Shimazawa et al., “Antiangiogenic Activity of Tumor Necrosis Factor-α Production Regulator Derived from Thalidomide,”Biol. Pham. Bull.22(2):224-226, 1999.
Shimazawa et al., “Novel Small Molecule Nonpeptide Aminopeptidase N Inhibitors with Cyclic Imide Skeleton,”J. Enzyme Inhibition14:259-275, 1999.
Teubert et al., “5′-Substituted Thalidomide Analogs as Modulators of TNF-α,” Arch. Pharm. Pharm. Med. Chem. 331:7-12, 1998.
Tsenova et al., “Use of IMiD3, a Thalidomide Analog, as an Adjunct to Therapy for Experimental Tuberculous Meningitis,”Antimicrobial Agents and Chemotherapy46(6):1887-1895, 2002.
Weinz et al., “Investigation of the in vitro biotransformation and simultaneous enantioselective separation of thalidomide and its neutral metabolites by capillary electrophoresis,”Journal of Chromatography B674:287-292, 1995.
Zhu et al., “Thiothalidomides: Novel Isosteric Analogues of Thalidomide with Enhanced TNF-α Inhibitory Activity,”J. Med. Chem.26(24):5222-5229, 2003.
Bartlett et al., “Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patents with metastatic malignant melanoma and other advanced cancers,”British Journal of Cancer90:955-961, 2004.
Bauer et al., “Inhibition of Angiogenesis by Thalidomide Requires Metabolic Activation, Which is Species-dependent,”Biochemical Pharmacology55:1827-1834, 1998.
Ch

Affiliated with

Also associated with

Rating

Thalidomide analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thalidomide analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thalidomide analogs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2671619